

YIELD10 BIOSCIENCE, INC.
CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share amounts)

	December 31, 2023	December 31, 2022
Assets		
Current Assets:		
Cash and cash equivalents	\$ 1,068	\$ 2,356
Short-term investments	—	1,991
Unbilled receivables	—	30
Prepaid expenses and other current assets	332	641
Total current assets	1,400	5,018
Restricted cash	264	264
Property and equipment, net	548	775
Right-of-use assets	1,653	1,961
Other assets	42	67
Total assets	\$ 3,907	\$ 8,085
Liabilities and Stockholders' Equity (Deficit)		
Current Liabilities:		
Accounts payable	\$ 1,202	\$ 109
Accrued expenses	2,010	926
Lease liabilities	669	575
Convertible note payable, net of issuance costs (Note 12)	984	—
Total current liabilities	4,865	1,610
Lease liabilities, net of current portion	1,525	2,075
Total liabilities	6,390	3,685
Commitments and contingencies (Note 7)		
Stockholders' Equity (Deficit):		
Preferred stock (\$0.01 par value per share); 5,000,000 shares authorized; no shares issued or outstanding	—	—
Common stock (\$0.01 par value per share); 60,000,000 shares authorized at December 31, 2023 and 2022, and 12,032,425 and 4,944,202 shares issued and outstanding at December 31, 2023 and 2022, respectively	120	49
Additional paid-in capital	411,814	404,277
Accumulated other comprehensive loss	(265)	(229)
Accumulated deficit	(414,152)	(399,697)
Total stockholders' equity (deficit)	(2,483)	4,400
Total liabilities and stockholders' equity (deficit)	\$ 3,907	\$ 8,085

The accompanying notes are an integral part of these consolidated financial statements.